Business
Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19
Hamsters Receiving Ainos' VELDONA Formulation Demonstrate Protection from COVID-19 Based on Prespecified Indicators of Clinical Outcomes SAN DIEGO, June 27,
About this update from Ainos, Inc.
[{"type":"text","content":"Hamsters Receiving Ainos' VELDONA Formulation Demonstrate Protection from COVID-19 Based on Prespecified Indicators of Clinical Outcomes\nSAN DIEGO, June 27, 2022 /PRNewswire/ -- Ainos, Inc. (OTC PINK: AIMD) (\"Ainos\", or the \"Company\"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the topline results from its COVID-19 antiviral efficacy study in hamsters (the \"Study\"). The available results show that its low-dose oral interferon alpha (\"IFN-α\") formulation, VELDONA, has a protective effect on lungs infected with the SARS-CoV-2 (the \"Delta variant\") virus by regulating the immune response, thus expediting recovery of infected animals. The Company will begin to prepare the application documents for U.S. FDA Phase 2/3 clinical trials. Further information regarding the Study can be found on the Company's website (https://www.ainos.com/support/en/listbypid/18).\nThe Study evaluates the effectiveness of VELDONA over a seven-day course of treatment of Delta-variant-infected hamsters. Compared with hamsters in the control group receiving solution without VELDONA (the \"Control Group\"), the hamsters in the group receiving solution with VELDONA (the \"VELDONA Group\") demonstrated resistance to body weight loss during the first four days, then showed a similar recovery trend in the following two days. The body weights of the hamsters in the VELDONA Group remained more stable than those of the hamsters in the Control Group. Among the symptoms exhibited by hamsters infected with SARS-CoV-2 are interferon dysregulation and loss of body weight. VELDONA increases the secretion of interferon in the body, thereby enhancing immunoreaction.\nPercentage of Weight Change\n\nDelta variant viral infection mainly occurs in the upper respiratory tract, but in severe cases it will extend to the lower respiratory tract (i.e., the lungs) causing serious irreversible complications. The Study found that on the sixth day after infection, the amount of virus in the nasal cavities of the hamsters in the VELDONA Group declined significantly, with a maximum reduction ratio of 551.16. More importantly, hamsters in the VELDONA Group had less virus present in the lungs on the third day, and on the sixth day, the ham...